ClinicalTrials.gg
CompletedNCT00159887Updated Feb 1, 2021

Study to Assess the Longterm Safety of Sildenafil Citrate in Patients With Pulmonary Arterial Hypertension

A Phase 3 interventional study of Sildenafil citrate in Pulmonary Hypertension, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 65 sites in 22 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-02-01.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
260
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 51 studies testing sildenafil in Hypertension, Pulmonary — 1 open to participants now, 1 under way, none of them phase 3. sildenafil · Hypertension, Pulmonary.

Enrollment
4th of 50
260 · median 30
Started
2002
with 1 other
Phase 3
15 of 51
none open now
Registered
3rd of 51
by date
Lead sponsor
7 of 51
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Among the 51 studies testing sildenafil in Hypertension, Pulmonary, this one is the 4th largest by enrollment of the 50 interventional ones that give a count, is one of 2 that started in 2002, is one of 15 in phase 3, and was the 3rd registered.

Hypertension, Pulmonary

1,092 studies on the registry are indexed under Hypertension, Pulmonary; 244 are open to participants now.

Browse Hypertension, Pulmonary studies →

Open to participants now

1 of the 51 studies testing sildenafil in Hypertension, Pulmonary is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About sildenafil

sildenafil: first FDA approval 1998 (VIAGRA), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 164 Hypertension, Pulmonary studies recruiting now, 99 (60%) set no upper age limit and 26 (16%) stop at 75 or younger; 39 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies testing sildenafil in Hypertension, Pulmonary, or all of them as a file.
02

Study summary

Open label extension study to the pivotal efficacy study to assess the safety of sildenafil citrate in patients with pulmonary arterial hypertension

03

Conditions studied

  • Pulmonary Hypertension
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with PAH who had completed the 12 week pivotal study

Exclusion criteria

Exclusion Criteria:

  • Any other patients with PAH that had not been included into the pivotal study
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
260 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. Safety

  2. Standard safety data

  3. Efficacy

  4. 6-Minute Walk Test

  5. BORG Dyspnoea Score

  6. WHO Functional Class

  7. Quality of Life SF-36 and EQ-5D

07

Study locations

65 sites
  • Pfizer Investigational Site
    Birmingham, Alabama 35233, United States
  • Pfizer Investigational Site
    Birmingham, Alabama 35294-0006, United States
  • Pfizer Investigational Site
    Birmingham, Alabama 35294, United States
  • Pfizer Investigational Site
    La Jolla, California 92037, United States
  • Pfizer Investigational Site
    La Jolla, California 92093, United States
  • Pfizer Investigational Site
    Los Angeles, California 90024, United States
  • Pfizer Investigational Site
    Los Angeles, California 90033, United States
  • Pfizer Investigational Site
    Los Angeles, California 90073, United States
  • Pfizer Investigational Site
    Los Angeles, California 90095, United States
  • Pfizer Investigational Site
    San Diego, California 92103-8320, United States
  • Pfizer Investigational Site
    Torrance, California 90502, United States
  • Pfizer Investigational Site
    Denver, Colorado 80220, United States
  • Pfizer Investigational Site
    Denver, Colorado 80262, United States
  • Pfizer Investigational Site
    Chicago, Illinois 60637, United States
  • Pfizer Investigational Site
    Baltimore, Maryland 21287, United States
  • Pfizer Investigational Site
    Boston, Massachusetts 02111, United States
  • Pfizer Investigational Site
    Ann Arbor, Michigan 48109, United States
  • Pfizer Investigational Site
    Rochester, Minnesota 55905, United States
  • Pfizer Investigational Site
    New York, New York 10032, United States
  • Pfizer Investigational Site
    Durham, North Carolina 27710, United States
  • Pfizer Investigational Site
    Nashville, Tennessee 37232-5735, United States
  • Pfizer Investigational Site
    Nashville, Tennessee 37232, United States
  • Pfizer Investigational Site
    Houston, Texas 77030, United States
  • Pfizer Investigational Site
    Milwaukee, Wisconsin 53215, United States
  • Pfizer Investigational Site
    Darlinghurst, New South Wales 2010, Australia
  • Pfizer Investigational Site
    Melbourne, Victoria 3004, Australia
  • Pfizer Investigational Site
    Bruxelles, 1070, Belgium
  • Pfizer Investigational Site
    Leuven, 3000, Belgium
  • Pfizer Investigational Site
    Sao Paulo, SP 05403-900, Brazil
  • Pfizer Investigational Site
    Prague 4, 140 00, Czechia
  • Pfizer Investigational Site
    Prague 4, 140 21, Czechia
  • Pfizer Investigational Site
    Kobenhavn, 2100, Denmark
  • Pfizer Investigational Site
    Clamart Cedex, 92141, France
  • Pfizer Investigational Site
    Giessen, 35392, Germany
  • Pfizer Investigational Site
    Hannover, 30625, Germany
  • Pfizer Investigational Site
    Leipzig, 04103, Germany
  • Pfizer Investigational Site
    Shatin NT, Hong Kong
  • Pfizer Investigational Site
    Budapest, 1529, Hungary
  • Pfizer Investigational Site
    Zalaegerszeg, 8900, Hungary
  • Pfizer Investigational Site
    Petach Tikva, 49100, Israel
  • Pfizer Investigational Site
    Tel Hashomer, 52621, Israel
  • Pfizer Investigational Site
    Bologna, 40138, Italy
  • Pfizer Investigational Site
    Pisa, 56124, Italy
  • Pfizer Investigational Site
    Pisa, 56126, Italy
  • Pfizer Investigational Site
    Suwon, 443-721, Korea, Republic of
  • Pfizer Investigational Site
    Kuala Lumpur, 59100, Malaysia
  • Pfizer Investigational Site
    Petaling Jaya, 46200, Malaysia
  • Pfizer Investigational Site
    Tlalpan Mexico, DF 14050, Mexico
  • Pfizer Investigational Site
    Tlalpan, Mexico DF 14080, Mexico
  • Pfizer Investigational Site
    Amsterdam, 1081 HV, Netherlands
  • Pfizer Investigational Site
    Warszawa, 01-138, Poland
  • Pfizer Investigational Site
    Zabrze, 41-800, Poland
  • Pfizer Investigational Site
    Singapore, 168752, Singapore
  • Pfizer Investigational Site
    Parow, Western Cape 7505, South Africa
  • Pfizer Investigational Site
    Parktown West, 2193, South Africa
  • Pfizer Investigational Site
    Parktown, 2193, South Africa
  • Pfizer Investigational Site
    Barcelona, 08035, Spain
  • Pfizer Investigational Site
    Barcelona, 08036, Spain
  • Pfizer Investigational Site
    Madrid, 28041, Spain
  • Pfizer Investigational Site
    Goteborg, 41345, Sweden
  • Pfizer Investigational Site
    Papworth Everard, Cambridgeshire CB3 8RE, United Kingdom
  • Pfizer Investigational Site
    Sheffield, South Yorkshire S10 2JF, United Kingdom
  • Pfizer Investigational Site
    Newcastle Upon Tyne, Tyne And Wear NE7 7DN, United Kingdom
  • Pfizer Investigational Site
    Cambridge, CB4 9EL, United Kingdom
  • Pfizer Investigational Site
    Glasgow, G11 6NT, United Kingdom
08

References and documents

Publications

  • Wirostko BM, Tressler C, Hwang LJ, Burgess G, Laties AM. Ocular safety of sildenafil citrate when administered chronically for pulmonary arterial hypertension: results from phase III, randomised, double masked, placebo controlled trial and open label extension. BMJ. 2012 Feb 21;344:e554. doi: 10.1136/bmj.e554. PubMed 22354598 ↗
  • Rubin LJ, Badesch DB, Fleming TR, Galie N, Simonneau G, Ghofrani HA, Oakes M, Layton G, Serdarevic-Pehar M, McLaughlin VV, Barst RJ; SUPER-2 Study Group. Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study. Chest. 2011 Nov;140(5):1274-1283. doi: 10.1378/chest.10-0969. Epub 2011 May 5. PubMed 21546436 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2002 and a completion of Feb 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2005
First posted
Sep 12, 2005
Start
Dec 2002
CompletionActual
Feb 2007
Last update
Feb 1, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 1, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00159887
Responsible party
Sponsor
First posted
Sep 12, 2005
Start date
Dec 2002
Completion
Feb 2007
Last update
Feb 1, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sildenafil

Start the discussion